Corbion (CRBN) Q3 2024 earnings summary

Executive summary

• Achieved organic sales growth of 2.6% and volume/mix growth of 6.1% for the first nine months of 2024, with Q3 organic sales up 9.2% year-over-year.

• Adjusted EBITDA rose 31.2% year-over-year to €135.7 million, with Q3 Adjusted EBITDA up 44.2% to €49.6 million.

• Free cash flow (excluding divestments) reached €50.8 million YTD, with guidance raised to over €60 million for the year.

• Health & Nutrition segment delivered double-digit sales and Adjusted EBITDA growth, led by Omega-3 DHA and strong performance across all sub-segments.

• Functional Ingredients & Solutions saw positive volume/mix growth, especially in Food, despite pricing pressure in basic lactic acid.

Financial highlights

• Net sales from continued operations were €972.9 million YTD, up 2.2% year-over-year; Q3 sales were €335.8 million, up 8.1%.

• Adjusted EBITDA margin improved to 13.9% YTD and 14.8% in Q3, up from 10.9% and 11.1% last year.

• Free cash flow reached €50.8 million YTD and €38.1 million in Q3.

• Health & Nutrition sales grew 21.4% year-over-year, with Adjusted EBITDA up 90.6%.

• Functional Ingredients & Solutions sales declined 2.4% year-over-year, but Adjusted EBITDA rose 2.3%.

Outlook and guidance

• Upgraded 2024 guidance: volume/mix growth above 5%, Adjusted EBITDA organic growth 22–25%, and free cash flow over €60 million (excluding divestments).

• Pricing expected to remain low single-digit negative due to input cost relaxation.

• Covenant net debt/EBITDA expected at 2.0–2.2x by year-end.

• 2025 EBITDA target of €226 million reaffirmed, with cost-saving initiatives on track.